AP&T: 长期使用聚乙二醇干扰素治疗慢性丁型肝炎可以获得持久的病毒学反应和功能性治愈

2021-06-29 MedSci原创 MedSci原创

丁型肝炎病毒 (HDV) 是最具侵袭性的慢性病毒性肝炎,这部分患者对1至2年的聚乙二醇干扰素α(聚乙二醇干扰素)治疗的反应率并不理想。

      丁型肝炎病毒 (HDV) 是最具侵袭性的慢性病毒性肝炎,这部分患者对1至2年的聚乙二醇干扰素α(聚乙二醇干扰素)治疗的反应率并不理想。本项研究旨在评估长期服用聚乙二醇干扰素后慢性丁型肝炎患者的长期预后情况。

 

      研究人员对接受聚乙二醇干扰素治疗的丁型肝炎患者进行了长期的随访,并根据病毒学反应进行分类,完全治愈定义为在最后一次随访时血清中HDV RNA 完全丢失,同时,在长期随访期间,记录了患者的生存情况和肝脏相关事件的发生情况。

 

      研究结果显示,接受超过 6 个月的聚乙二醇干扰素治疗的总共有12名患者。该队列主要是白人 (83%) 和男性 (92%),年龄从 18 岁到 58 岁不等。大多数患者在基线时患有晚期但代偿性肝病,中位 HBV DNA 水平为 536 IU/mL,中位 HDV RNA 水平为 6.86 log10基因组当量/mL。治疗持续时间平均为 6.1 年,总随访时间为 8.8 年。在最后一次随访时,7 名 (58%) 患者的血清中检测不到 HDV RNA,4 名 (33%) 患者清除了 HBsAg。

 

      本项研究发现延长聚乙二醇干扰素治疗过程可以让超过一半的丁型肝炎患者体内 HDV RNA 清除,三分之一的患者 HBsAg 消失。

 

 

原始出处:

Julian Hercun. Et al. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy. Alimentary Pharmacology & Therapeutics.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2022-02-03 weiz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-07-01 周虎
  6. [GetPortalCommentsPageByObjectIdResponse(id=1755218, encodeId=77221e5521843, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Thu Feb 03 16:19:33 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194218, encodeId=952e11942184b, content=<a href='/topic/show?id=daeb48e14ef' target=_blank style='color:#2F92EE;'>#干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48714, encryptionId=daeb48e14ef, topicName=干扰素)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Wed Feb 16 22:51:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915556, encodeId=1ba5191555689, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Mon Mar 07 16:19:33 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010186, encodeId=50142010186a7, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sun Dec 05 20:19:33 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603367, encodeId=1834160336e3a, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Thu Jul 01 13:19:33 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978059, encodeId=502b9e80595a, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee45099722, createdName=鑫**, createdTime=Tue Jun 29 23:22:38 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-06-29 鑫**

    努力学习中

    0

相关资讯

REVTx-99治疗COVID-19:即将开展I期临床研究

生物制药公司Revelation Biosciences今天宣布,已获得澳大利亚人类研究伦理委员会(HREC)的批准,允许在健康志愿者中进行REVTx-99的I期临床研究(RVL-HV01研究)。

J Allergy Clin Immunol:哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加

急性呼吸道病毒感染是呼吸道发病和死亡的主要原因,尤其是对于已有肺部疾病如哮喘的患者。Toll样受体(TLRs)在早期病毒检测和激活呼吸道黏膜先天性免疫中起着关键作用,但目前还没有可靠、方便的方法来检测

Cell :机制不明,肠道菌群...哈佛耶鲁科学家《Cell》揭开其抗病毒机制的面纱

众所周知,肠道菌群对人体健康具有包括从心理健康到生理健康的一系列深远影响,而且已经得到了充分证实。然而,肠道菌群在天然抵抗病毒感染中发挥重要作用的这一机制至今还未查明。

Neurology:干扰素信号抑制,不会干扰帕金森病风险或发病年龄

干扰素信号抑制,不会干扰帕金森病风险或发病年龄

“模拟病毒的药物”可帮助免疫系统靶向狡猾的癌细胞

加州大学洛杉矶分校(UCLA)的研究人员发现,一种像病毒一样激活人体自然防御能力的药物可能使某些隐形的黑色素瘤细胞对免疫系统可见,从而可以通过免疫疗法更好地攻击这些癌细胞。

STTT:新冠病毒M蛋白抑制I和III型干扰素激活,实现免疫逃逸

新冠病毒(SARS-CoV-2)是单链(+)RNA 病毒,可以跨物种传播并感染人类。SARS-CoV-2感染导致的新冠肺炎(COVID-19)已经在全球大流行。